Home » Newsletters » BioWorld Science

BioWorld Science

June 1, 2004

View Archived Issues

Medivir continued to make progress during interim period

Update on natalizumab in Crohn's disease

Therapeutic benefits of cilansetron in IBS

Semapimod suggested to be effective in Crohn's disease

Pharmacokinetics and safety of fontolizumab in Crohn's disease

MorphoSys highlights Q1 developments

Telik highlights Q1 developments

Extracts from Korean red ginseng roots reduce blood pressure in hypertensive patients

TLR2 antibody may prevent septic shock

Oncolytic adenovirus targets colon cancer cells with deregulated wnt pathway in vivo

Novel anti-HIV agent targets RNase H activity

Novel small molecule inhibitor of human rotavirus

SciClone and Nektar Therapeutics collaborate on pegylated Zadaxin

European approval for new Enbrel indication

LC16m8 smallpox vaccine demonstrates effectiveness in animal studies

Approval for Gonal-f Pen for infertility

Pharmaceutical Resources changes name to Par Pharmaceutical Companies

FDA sets date to discuss Macugen NDA

Dosing commences in phase II trial of Albuferon for chronic HCV

Enrollment under way in confirmatory phase III trial of Sebazole

Orphan drug status for PD-6735

Anadys selects ANA-975 as development candidate for HCV

AEterna Zentaris unveils new name, progress and plans

Atiprimod enters new phase I/II trial in relapsed multiple myeloma

Zemplar approved for pediatric use

UCB to acquire Celltech

Encore claims esters of R-NSAIDs and their therapeutic use

Two series of MMP, TACE and/or aggrecanase inhibitors presented by BMS

Dual PDE3/L-type Ca2+ channel inhibitors covered by Artesian patent

Novel beta2-adrenoceptor agonists discovered at Boehringer Ingelheim

New aminopeptidase N inhibitors and their use in atherosclerosis and other disorders

Roche researchers describe 5-HT receptor ligands for psychoses, dementia, etc.

Pfizer claims novel p38 MAP kinase inhibitors in a recent patent

Cizolirtine completes phase II trials in urinary incontinence